A special remark is made to near-infrared photoimmunotherapy directed at CD44 and CD133, which are not only considered markers of CSCs in breast cancer and glioblastoma but also in HNSCC (Kobayashi and Choyke, 2019). The gene discussed is CD44; the disease is breast carcinoma.